Generer rapport
Novartis Healthcare A/S
Edvard Thomsens Vej 14, 3, 2300 København S, CVR 20575786
Virksomhedsform
Aktieselskab
Etableret
1997
Størrelse
Mellemstore
Ansatte
128
Omsætning
593
MDKK
Bruttofortj.
193
MDKK
Primært resultat (EBIT)
20
MDKK
Årets resultat
56
MDKK
Egenkapital
290
MDKK
annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
16/444
"Top 10%"
Rang i Danmark
2.739/343.294
"Top 10%"
Direktion top 3
Peter Drøidal 6 | CEO |
Bestyrelse top 3
Uffe Mark Hansen 1 | Bestyrelsesformand |
Peter Drøidal 6 | Bestyrelsesmedlem |
Johan Mikael Olof Kahlström 1 | Bestyrelsesmedlem |
Legale ejere top 3
100% | Novartis Pharma AG | CH |
Tegningsregler
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af en direktør i forening med et bestyrelsesmedlem
Stamoplysninger baseret på CVR
Navn | Novartis Healthcare A/S |
Binavne | Ciba-Geigy A/S, Sandoz A/S Vis mere |
CVR | 20575786 |
Adresse | Edvard Thomsens Vej 14, 3, 2300 København S |
Branche | Engroshandel med medicinalvarer og sygeplejeartikler [464610] |
Etableret | 17-12-1997 (26 år) |
Første regnskabsperiode | 01-04-1997 til 31-12-1997 |
Virksomhedsform | Aktieselskab |
Antal ansatte | 95 (årsværk:91) |
Reklamebeskyttelse | Nej |
Revisor | Kpmg P/S siden 06-01-2023 |
Regnskabsperiode | 01-01 til 31-12 |
Selskabskapital | 14.001.000 DKK 12.001.000 DKK (15-12-2006 - 18-08-2009) 10.001.000 DKK (14-12-2004 - 14-12-2006) 8.001.000 DKK (10-07-2002 - 13-12-2004) 8.000.000 DKK (17-12-1997 - 09-07-2002) |
Vedtægter seneste | 15-05-2020 |
Medlem af brancherne
- Engroshandel med medicinalvarer og sygeplejeartiklerNACE6 indeholdende 633 virk.
- Engroshandel med husholdningsartiklerNACE3 indeholdende 6.330 virk.
- Engroshandel undtagen med motorkøretøjer og motorcyklerNACE2 indeholdende 24.349 virk.
- Engroshandel og detailhandel, reparation af motorkøretøjer og motorcyklerNACE1 indeholdende 75.218 virk.
Formål
Selskabets formål er at drive handel, industri og finansiering samt anden dermed beslægtet virksomhed, herunder at drive virksomhed gennem datterselskaber
Regnskab
2022 | 2021 | 2020 | |
---|---|---|---|
Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
Omsætning | 592.697 -16% | 701.904 -30% | 1.002.386 +4% |
Bruttofortjeneste | 193.399 +13% | 170.533 -13% | 196.791 +15% |
Årets resultat | 56.162 -34% | 84.886 -34% | 127.707 - |
Egenkapital | 289.921 +24% | 233.759 +57% | 148.873 +603% |
Balance | 942.616 0% | 943.865 +15% | 820.852 +10% |
Ledelsesberetning
The income statement for 2022 shows a profit of DKK 56,162 thousand against a profit of DKK 84,886 last year, and the balance sheet at 31 December 2022 shows equity of DKK 289,921 thousand.
Actuals for the year 2022 didn’t reach the target set by the management. Sales being lower than target were partly driven by higher than anticipated LOE erosion (generic impact) as well as assumptions on winning certain tenders not materializing. There was also some impact from forward-buying in December 2021 which was not de-risked in the target.
In April 2022 Novartis globally announced a new organizational structure to accelerate growth and strengthen pipeline and increase productivity. This new simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity Integrating Pharmaceuticals and Oncology business units into an Innovative Medicines business with separate US and International commercial organizations will increase focus, strengthen competitiveness and drive synergies. This restructuring initiative has reduced the number of employees in Novartis Healthcare A/S. In terms of headcounts in payroll as of Dec 2022, there was no/low impact of TfG. Headcount has been reduced in 2023 and is reduced already at the time of issuing this annual report.
In August 2022 Novartis announced the intention to separate Sandoz business to create a standalone company by way of a 100% spin-off. For both the Innovative Medicines and Sandoz businesses, the spin-off would enable enhanced focus and the ability to pursue independent growth strategies. Sandoz is expected to deliver its next wave of growth based on the existing biosimilars pipeline of 15+ molecules, a strong and experienced management team and organization. Novartis aims to become a focused innovative medicines company with a stronger financial profile, and improved return on capital.
Actuals for the year 2022 didn’t reach the target set by the management. Sales being lower than target were partly driven by higher than anticipated LOE erosion (generic impact) as well as assumptions on winning certain tenders not materializing. There was also some impact from forward-buying in December 2021 which was not de-risked in the target.
In April 2022 Novartis globally announced a new organizational structure to accelerate growth and strengthen pipeline and increase productivity. This new simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity Integrating Pharmaceuticals and Oncology business units into an Innovative Medicines business with separate US and International commercial organizations will increase focus, strengthen competitiveness and drive synergies. This restructuring initiative has reduced the number of employees in Novartis Healthcare A/S. In terms of headcounts in payroll as of Dec 2022, there was no/low impact of TfG. Headcount has been reduced in 2023 and is reduced already at the time of issuing this annual report.
In August 2022 Novartis announced the intention to separate Sandoz business to create a standalone company by way of a 100% spin-off. For both the Innovative Medicines and Sandoz businesses, the spin-off would enable enhanced focus and the ability to pursue independent growth strategies. Sandoz is expected to deliver its next wave of growth based on the existing biosimilars pipeline of 15+ molecules, a strong and experienced management team and organization. Novartis aims to become a focused innovative medicines company with a stronger financial profile, and improved return on capital.
09-05-2023